CEL Stock Overview
Engages in the research, cultivation, manufacturing, and sale of cannabis-based medicines. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Celadon Pharmaceuticals Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.20 |
| 52 Week High | UK£1.23 |
| 52 Week Low | UK£0.11 |
| Beta | -0.20 |
| 1 Month Change | 36.67% |
| 3 Month Change | -22.64% |
| 1 Year Change | -77.84% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -85.86% |
Recent News & Updates
Recent updates
Shareholder Returns
| CEL | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 13.9% | 3.9% | 1.0% |
| 1Y | -77.8% | 11.5% | 12.1% |
Return vs Industry: CEL underperformed the UK Pharmaceuticals industry which returned 3.1% over the past year.
Return vs Market: CEL underperformed the UK Market which returned 10.2% over the past year.
Price Volatility
| CEL volatility | |
|---|---|
| CEL Average Weekly Movement | 35.2% |
| Pharmaceuticals Industry Average Movement | 7.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.7% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: CEL's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: CEL's weekly volatility has increased from 23% to 35% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 27 | Jim Short | celadonpharma.com/ |
Celadon Pharmaceuticals Plc engages in the research, cultivation, manufacturing, and sale of cannabis-based medicines. The company primarily focuses on growing indoor hydroponic cannabis for use in medicinal products. Its products used to treat chronic pain, as well as autism spectrum disorders.
Celadon Pharmaceuticals Plc Fundamentals Summary
| CEL fundamental statistics | |
|---|---|
| Market cap | UK£14.11m |
| Earnings (TTM) | -UK£5.23m |
| Revenue (TTM) | UK£130.00k |
108.6x
P/S Ratio-2.7x
P/E RatioIs CEL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CEL income statement (TTM) | |
|---|---|
| Revenue | UK£130.00k |
| Cost of Revenue | UK£91.00k |
| Gross Profit | UK£39.00k |
| Other Expenses | UK£5.27m |
| Earnings | -UK£5.23m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.076 |
| Gross Margin | 30.00% |
| Net Profit Margin | -4,024.62% |
| Debt/Equity Ratio | 1.3% |
How did CEL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/06 00:07 |
| End of Day Share Price | 2025/02/06 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Celadon Pharmaceuticals Plc is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.